A new market forecast from IndexBox projects the global collagen peptides tablets market growing at a compound annual rate of 5.8% from 2026 through 2035, with the market index reaching roughly 168 by 2035 against a 2025 baseline of 100.

Collagen peptides are hydrolyzed collagen, protein broken into shorter fragments, and the report defines the category narrowly: solid oral tablets marketed for beauty-from-within, joint health, and general wellness. That last phrase is doing a lot of work, and the report is refreshingly direct about the fact that this is a consumer-goods category shaped by shelf space and promotional calendars rather than by any technical specification.

A category splitting in two

IndexBox describes a market in what it calls structural bifurcation: mass-market commoditization on one side, premium benefit-specific branding on the other. Private label is gaining ground in the value tiers while branded players push into claims around skin elasticity, joint mobility, and post-exercise recovery.

The analysts say this is pushing brands to invest in clinical substantiation. Note the direction of causation there: the research spend is a response to competitive pressure on shelf, not the thing that created the category.

Where the demand sits

Beauty and skin health remains the largest application, with joint and bone health second, driven by aging populations and sports participation. Sports nutrition and recovery is described as relatively small but premium-priced.

Geographically, Asia-Pacific is both the largest region and the manufacturing hub, while North America and Western Europe are what the report calls premiumization engines. Named participants across segments include Vital Proteins, Shiseido, Haleon, Nestle Health Science, and GNC Holdings.

The regulatory question

The two risks IndexBox flags are worth more attention than the growth number. One is regulatory tightening on health claims, which the report expects to raise compliance costs and favor established players. The other is supply chain concentration for quality hydrolyzed collagen.

That first risk is the interesting one for anyone reading the category's marketing. A forecast built on benefit-specific branding is also a forecast that assumes regulators keep letting those benefits be stated.

Bottom line

IndexBox notes it uses indexed curves rather than absolute volumes because full figures are not publicly disclosed, so the 168 is a trajectory comparison, not a dollar value. The projection assumes continued consumer interest holds and that claims rules do not tighten faster than brands can substantiate.